- Bladder Cancer is the fourth most common cancer among men.
- Neutrophil to lymphocyte ratio (NLR) biomarker is useful in detecting the progress of bladder cancer.
- A new study from Penn Medicine finds NLR biomarker to be ineffective in determining treatment options for bladder cancer.
A new research study from the University of Pennsylvania School of Medicine found promising biomarker( neutrophil to lymphocyte ratio) in detecting cancer progress to be clueless or not reliable for determining the effective treatment options.
The research study was published in the journal Cancer this week.
Previous studies related to bladder cancer biomarker called neutrophil to lymphocyte ratio(NLR)was found to detect the worsening of overall survival rate after bladder cancer surgery (radial cystectomy). The blood test will also be capable of predicting the patients who will be benefit from presurgery chemotherapy.
Ojerholm said, "Dozens of earlier studies reported NLR as a biomarker for bladder cancer, and we hoped that this would be true."
"Yet extraordinary claims require extraordinary evidence. And all prior studies relied on observational datasets. Many also used statistical methods that can lead to false positive results. So we decided to rigorously put NLR to the test." he added.
The research team analyzed data collected from the SWOG 8710 clinical trial with 317 bladder cancer patients who had radial cystectomies. Out of which half of these patients had chemotherapy treatment prior to surgery.
"First, baseline blood samples were collected as part of the trial protocol. Second, the study's long-term follow-up gave us adequate 'statistical power,' meaning that if NLR really was a biomarker, then we should be able to detect it. Third, the trial randomly assigned some patients to receive pre-surgery chemotherapy. This allowed us to test NLR both as a prognostic and predictive biomarker." Ojerholm said.
The research team identified 230 patients for prognostic analysis and 263 patients for predictive analysis to determine the overall survival rate and chemotherapy benefits for bladder cancer respectively.
The study findings found both the analysis to have no significant results. And the author states it could be a problem of publication bias as authors fail to present negative results and sometimes journal also fails to accept them.
The author concludes that no single study could be definitive and more evidence and research is required before using this biomarker.
Please use one of the following formats to cite this article in your essay, paper or report:
Madhumathi Palaniappan. (2016, October 27). Bladder Cancer Biomarker Fails to Explain Treatment Strategies. Medindia. Retrieved on Sep 26, 2022 from https://www.medindia.net/news/healthwatch/bladder-cancer-biomarker-fails-to-explain-treatment-strategies-164685-1.htm.
Madhumathi Palaniappan. "Bladder Cancer Biomarker Fails to Explain Treatment Strategies". Medindia. Sep 26, 2022. <https://www.medindia.net/news/healthwatch/bladder-cancer-biomarker-fails-to-explain-treatment-strategies-164685-1.htm>.
Madhumathi Palaniappan. "Bladder Cancer Biomarker Fails to Explain Treatment Strategies". Medindia. https://www.medindia.net/news/healthwatch/bladder-cancer-biomarker-fails-to-explain-treatment-strategies-164685-1.htm. (accessed Sep 26, 2022).
Madhumathi Palaniappan. 2021. Bladder Cancer Biomarker Fails to Explain Treatment Strategies. Medindia, viewed Sep 26, 2022, https://www.medindia.net/news/healthwatch/bladder-cancer-biomarker-fails-to-explain-treatment-strategies-164685-1.htm.